This suggests that the effect of BMI on PASC risk is not only mediated by inflammation (as indicated by the association of obesity at COVID-19 onset with raised TNFα, sCD163 and CRP at 21–24 weeks), but also by additional physiological and metabolic processes [36]. Here, CD163 is linked to obesity disorder.